Germany - immunosuppressants

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
26 January 2020
Opportunity publication date
01 March 2019
Category
33652300
Value of contract
to be confirmed
Your guide to exporting
Report opportunity

Description

With regard to the active substance infliximab (ATC code: L04AB02), parenteral preparations of finished medicinal products for direct medical use manufactured in pharmacies, the AOK - Die Gesundheitskasse für Niedersachsen offers to all interested pharmaceutical companies, without a selection decision, discount contracts for the period until the entry into force of exclusive contracts following a formal award procedure in accordance with the rules of Part Four of the ARC. Contracts are concluded within the framework of an open-house model. The offered contracts are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform - individual negotiations are generally not conducted. The contract periods are a maximum of twelve months, the earliest commencement date being 1.4.2019. All contracts expire on 31.3.2020 at the latest, irrespective of the date on which the contract was concluded. An accession or a contract conclusion can take place within the twelve-month period in each case to the first of a month. There is a right of termination six weeks to the end of each month. The AOK - Die Gesundheitskasse für Niedersachsen reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts during the term of the contract. When exclusive discount contracts put out to tender come into force, the open-house contracts are terminated in accordance with the contractual provisions, i.e. the open-house contracts end automatically. Interested pharmaceutical companies can request the contract documents as well as the contractual conditions at the contact address given under I.1).Contracts for the active substance Infliximab (ATC code: L04AB02), for parenteral preparations of finished medicinal products manufactured in pharmacies for direct medical use, will be concluded for the first time with effect from 1.4.2019. Interested parties who wish to become contractual partners on this date must submit the contract documents to be submitted to the address specified in the contract documents by 7 March 2019. It depends on the access to the AOK Niedersachsen. Contracts may be concluded at a later date during the twelve-month maximum term on the first day of each month. In terms of organisation, the AOK usually needs a preliminary run of 35 calendar days in order to be able to guarantee the necessary work, e.g. the notification of the contract in the Lauer-Taxe®. The exact deadlines for receipt will be announced together with the contract documents. This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive (2004/18/EC) or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice shall be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this announcement form and the publication platform. This does not imply any further significance, in particular subordination to subcontracting regulations, unless they are mandatory for legal reasons.

Opportunity closing date
26 January 2020
Value of contract
to be confirmed

About the buyer

Address
AOK – Die Gesundheitskasse für Niedersachsen Hildesheimer Str. 273 Hannover 30519 Germany
Contact
rabattvertraege@nds.aok.de

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?